Mylan Defends King Deal, Cites “Growing Appreciation” Among Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Investor feedback on merger is “positive,” Mylan says in response to attempt by investor Carl Icahn to block proposed deal. Mylan dismisses Icahn’s opposition as opportunistic.
You may also be interested in...
Icahn's $5.4 Bil. Bid For Mylan Leaves Door Open To A "White Knight" Suitor
Investor offers $20 per share, a 17% premium over Mylan's closing price a day earlier. Icahn suggests other pharma companies are potentially interested in buying the generic drug maker and is proposing an acquisition contract with no break-up fee so that Mylan could pursue other offers.
Icahn's $5.4 Bil. Bid For Mylan Leaves Door Open To A "White Knight" Suitor
Investor offers $20 per share, a 17% premium over Mylan's closing price a day earlier. Icahn suggests other pharma companies are potentially interested in buying the generic drug maker and is proposing an acquisition contract with no break-up fee so that Mylan could pursue other offers.
Altace Patent Suit Cited By Icahn In Latest Missive Against Mylan/King Merger
Investor maintains that Cobalt Pharmaceuticals' patent challenge could mean a generic version of the ACE inhibitor will be launched in mid-2005. Mylan suggests that Icahn's opposition is motivated in part by desire to cash-in on short position in King.